Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate how...

Descripción completa

Detalles Bibliográficos
Autores principales: Berthold, Heiner K., Seidah, Nabil G., Benjannet, Suzanne, Gouni-Berthold, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609731/
https://www.ncbi.nlm.nih.gov/pubmed/23544125
http://dx.doi.org/10.1371/journal.pone.0060095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609731/
https://www.ncbi.nlm.nih.gov/pubmed/23544125
http://dx.doi.org/10.1371/journal.pone.0060095

Ejemplares similares